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Abstract: Adequate control of comorbidity has long been recognized as a critical challenge 
in clinical epidemiology. Comorbidity scales reduce information about coexistent disease to a 
single index that is easy to comprehend and statistically effi cient. These are the main advantages 
of an index over incorporating each disease into an analysis as an individual variable. Many 
study populations have a low prevalence of subjects with high comorbidity scores, so it is com-
mon to combine subjects with some score above a threshold into a single open-ended category. 
This paper examines the impact of collapsing comorbidity scores into these categories. It shows 
analytically and by synthetic example that collapsing the high-end categories of a comorbid-
ity scale changes the pattern of effect of comorbidity. Furthermore, collapsing the high-end 
categories biases analyses that control for comorbidity as a confounder or analyze modifi cation 
of an exposure’s effect by comorbidity. Each of these results specifi c to comorbidity scoring 
derives from more general epidemiologic principles. The appeal of collapsing categories to 
facilitate interpretation and statistical analysis may be offset by misleading results. Analysts 
should assure the uniformity of outcome risk in collapsed categories, informed by judgment 
and possibly statistical testing, or use analytic methods, such as restriction or spline regression, 
which can achieve similar goals without sacrifi cing the validity of results.
Keywords: epidemiologic factors, comorbidity, epidemiologic factors, bias (epidemiology)
Introduction
A recent US National Institute on Aging Task Force defi ned comorbidity as “the 
co-occurrence of preexisting age-related health conditions (eg, disability, anemia, 
impairments, urinary incontinence) or diseases (eg, diabetes, heart disease, hyperten-
sion) in reference to an index disease (eg, cancer, Parkinson’s disease, diabetes).”1 
Adequate measurement and analytic control of comorbidity has long been recognized 
as a critical challenge in clinical epidemiology.2 The aforementioned task force has 
reviewed the methodology of measurement of comorbidity,3 including the nosology 
of disease classifi cation4 and strategies to include disease severity in comorbidity 
scales.5
Collapsing comorbid diseases into a single scale provides an index that is easy to 
comprehend and statistically effi cient, which are the main advantages of an index over 
incorporating each disease into an analysis as an individual variable.6 A simple sum 
of the number of comorbid diseases treats each disease equivalently, thereby ignoring 
differences in the severity of the component diseases and differences in the severity 
of the disease state in different patients. Weighting schemes have been proposed and 
implemented to address each of these shortcomings.5,7 Whether summing diseases 
included in the index or weighting them by severity, all comorbidity schemes inevitably 
misclassify study subjects with respect to the idealized true scale of comorbidity.3 The 
impact of this misclassifi cation on the analytic results depends on whether comorbidity 
is the exposure of interest, study outcome, a confounder, or modifi er.3
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In most study populations, the prevalence of subjects with 
high comorbidity scores is low. It is common, therefore, to 
combine subjects with some score above a threshold into a 
single open-ended category. For example, the Charlson Index 
can theoretically range from 0 to 33 but was collapsed into 
categories of 0, 1–2, 3–4, and 5 in its initial presentation.7 
Similar examples, particularly examples of collapsing the 
scores in the highest categories, are easy to fi nd, even in 
this author’s own work.8 The rationale for collapsing these 
categories is the same as the rationale for using an index 
of comorbid diseases: ease of comprehension and statisti-
cal effi ciency. The effect of collapsing these categories is 
also the same as the effect of collapsing disparate comorbid 
diseases: introduction of classifi cation errors. In this paper, 
we show analytically and by synthetic example that collaps-
ing the high-end categories of a comorbidity scale changes 
the estimate(s) of effect(s) of comorbidity and biases analy-
ses that control for comorbidity as a confounder or analyze 
modifi cation of an exposure’s effect by comorbidity.
Methods and results
To depict the bias introduced by collapsing categories 
of a comorbidity scale, we created a scale with a strictly 
monotonically increasing risk of the outcome (r
i
) with each 
increase in the ordinal comorbidity scale (indexed by i), and 
a strictly monotonically decreasing prevalence (p
i
) of the 
comorbidity value with each increase in the ordinal comor-
bidity scale. Table 1 depicts this synthesized data. While the 
data are synthetic, we note that the risks of an outcome in the 
scale categories and the prevalence of the scale categories 
correspond well with values one might observe. For example, 
one might anticipate similar data if the population was an 
older population (say 70-years-old and older), if the index of 
comorbidity was the Charlson Index, and the outcome was 
a three-year risk of death.
Collapsing categories changes 
the estimate of comorbidity’s effect
The prevalence of the comorbidity categories decreases as 
the ordinal value increases. The prevalence of comorbidity 
category 4 is only 5%. In many data sets, the number of 
persons with this value would be small, and the number of 
cases of some outcome within that category even smaller. 
Analysts might be tempted to collapse category i = 4 with 
category i = 3, for example, to avoid sparse data problems 
or to improve the precision of the estimate of association in 
the highest comorbidity category. The effect of this collapse 
is to set the risk for the combined category to a weighted 
average of the two individual categories. More generally, 
collapsing a set of the upper-end categories ranging from 
i = v to the maximum (i = 4, in this example) generates a 
weighted average risk:
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Table 2 depicts the risk ratios (RR
C = x vs C = 0) estimated 
from the synthetic data when the high-end categories are 
collapsed together. The collapsed categories range from 
some value v, which can equal 1, 2, 3, or 4 to the maximum 
(4, in this example). Setting v = 4 therefore corresponds to 
the case in which there is no collapse. Note that collapsing 
categories does not introduce a bias; the estimate of risk 
and therefore risk ratio within each category is an accurate 
depiction of the effect in that category. With each additional 
combination, the risk in the highest category becomes more 
heavily weighted with the low-risk comorbidity categories 
because these low risk categories are more prevalent. When 
v = 1, which corresponds to a comparison of any comorbidity 
(collapsing categories 1 to 4) with no comorbidity (category 
i = 0), the risk ratio equals 12. This risk ratio is about fi ve-fold 
lower than the risk ratio in the highest comorbidity category 
(i = 4, in which the risk ratio equals 60) and about fi ve-fold 
higher than the risk ratio in the lowest category with any 
comorbidity (i = 1, in which the risk ratio equals 2.7). The risk 
ratio of 12 is not, in fact, a very good estimate of the effect 
Table 1 Depiction of the prevalence of comorbidity index categories 
(pi) and the risk of an outcome (ri) within the categories
Comorbidity category (i) 0 1 2 3 4
Prevalence (pi) 0.35 0.30 0.20 0.10 0.05
Risk (ri) 0.010 0.027 0.076 0.213 0.603
Table 2 Risk ratios associating the presence of comorbidity, compared 
with the absence of comorbidity, with the outcome within collapsed 
categories (ranging from v to 4)
Index of comorbidity (i)
v
0 
(Reference)
1 2 3 4
4 1 2.7 7.6 21 60
3 1 2.7 7.6 34
2 1 2.7 19
1 1 12
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of comorbidity in any of the most fi nely divided categories. 
Collapsing comorbidity categories can therefore diminish the 
ability to discern important patterns that are more apparent 
when categories are not collapsed.
Collapsing categories biases the relative 
risk due to confounding by comorbidity 
toward the null
Comorbidity data are frequently collected to control for con-
founding by underlying health indications. That is, comorbid 
diseases are likely to be more prevalent among patients 
with high risk conditions (eg, another health indicator such 
as frailty or disability) and likely also to be related to the 
outcome under study (eg, all-cause mortality). A scale of 
comorbid disease is therefore often a potential confounder 
and a candidate for analytic adjustment.
To examine the effect of collapsing comorbid categories 
when the comorbidity scale is used for analytic adjustment, 
we postulated a second dichotomous variable (E indexed by 
k = 0 or 1 within categories of the comorbidity scale) whose 
association with the outcome is of primary interest. We 
assumed that the prevalence of E = 1 depends on the category 
of the comorbidity scale, as depicted in Table 3. We assumed, 
however, that the risk of the outcome did not depend on the 
category of E within strata of the comorbidity scale. That 
is, after adjustment for the most fi nely divided comorbidity 
categories, the risk ratio associating E = 1 compared with 
E = 0 would be null (RR
E = 1 vs E = 0 = 1).
The crude risk in categories of E is the weighted average 
of the risks in Table 1, where now the weights correspond 
with the prevalence of comorbidity within category of E, as 
shown in Table 3. That is
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The risk equals 0.125 in E = 1 and 0.032 in E = 0, which 
yields a crude RR
E = 1 vs E = 0 of 3.90. The substantial depar-
ture of this crude risk ratio from the true null association 
is entirely due to confounding by comorbidiy. The relative 
risk due to confounding (RR
c
), which equals the ratio of 
the crude and adjusted estimates, provides a measure of the 
direction and magnitude of this confounding, and in this 
case RR
c
 = 3.9/1 = 3.9. To resolve the confounding, one can 
calculate the standardized risk ratio (sRR
E = 1 vs E = 0), where 
the standard weights equal the prevalence of the comorbidity 
categories in E = 1 (these weights are p
i, 1
). That is:
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when comorbidity categories are collapsed, the standardized 
risk in the denominator uses the weighted average risk in the 
collapsed category (r
v…4, 0
, where the weights come from the 
unexposed group) and the sum of corresponding weights in 
the exposed category (sum from v to 4 of p
i,1
).
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The resulting sRR is incompletely adjusted for confound-
ing by comorbidity. Table 4 depicts the sRR
E = 1 vs E = 0 and 
RR
c
 for this scenario, and in a second scenario with the true 
sRR
E = 1 vs E = 0 = 1.5. In both cases, collapsing the upper-end 
categories of the comorbidity scales yields incomplete con-
trol for confounding by comorbidity. The result is a bias of 
RR
c
 toward the null, which can give rise to the appearance 
of an association between E and the outcome when the true 
association is null (scenario 1), can give rise to the appearance 
of a stronger association than is truly present (scenario 2), 
or can give rise to an underestimate of the true association 
Table 4 Depiction of the true sRRE = 1 vs E = 0 and RRc (v = 4) and 
biased sRRE = 1 vs E = 0 and RRc (v  4) when comorbidity categories 
are collapsed
v Scenario 1 Scenario 2
sRRE = 1 vs E = 0
RRc sRRE = 1 vs E = 0
RRc
4 1.00 3.90 1.50 4.36
3 1.45 2.68 2.32 2.81
2 1.63 2.40 2.60 2.51
1 2.42 1.61 3.96 1.65
Table 3 Depiction of the prevalence of comorbidity index categories 
within categories of E (pi, k)
Comorbidity category (i) 0 1 2 3 4
Prevalence in E = 1 (pi,1) 0.15 0.30 0.30 0.15 0.10
Prevalence in E = 0 (pi,0) 0.55 0.30 0.10 0.05 0.00
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if the true RR
c
  1 and the true association between E and 
the outcome is causal.
Collapsing categories biases estimates 
of interaction unpredictably
Some analyses examine the interaction between comorbid 
disease and a second variable. These analyses investigate 
whether the effect of the exposure depends on the comorbid-
ity category. Often the analysis compares the effect of the 
exposure in those with the highest comorbidity category to 
the effect of the exposure in those with the lowest comorbid-
ity category. For example, one might calculate the interac-
tion contrast (IC),9 which measures the departure of risk in 
those with the high risk category of the exposure (E = 1) and 
comorbidity (I = 4) from the risk expected given (a) the inde-
pendent effect of the exposure in those without comorbidity 
(r
0, 1
 – r
0, 0
), (b) the independent effect of higher comorbid-
ity in those without the exposure (r
4, 0
 – r
0, 0
), (c) the risk in 
those with the low risk category of the exposure (E = 0) and 
comorbidity (I = 0). This concept simplifi es to the risk differ-
ence in those with high comorbidity less the risk difference 
in those without comorbidity. That is:
IC r r r r r r
r r r r
= − − − − −
= − − −
4 1 0 1 0 0 4 0 0 0 0 0
4 1 4 0 0 1 0
, , , , , ,
, , , ,
( ) ( )
( ) ( 0 )
A second measure of interaction is the ratio of the risk 
ratios, which we will call effect measure modification 
(EMM). That is:
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When the highest categories of comorbidity are collapsed, 
however, r
4,1
 will be replaced with r
v…4,1
 and r
4,0
 will be 
replaced with r
v…4,0
. The result is an unpredictable bias in 
the estimates of the interaction between the exposure and 
comorbidity. In scenario 1, the exposure has no effect, so 
r
i,1
 – r
i,0
 = 0 and r
i,1
/r
i,0
 = 1. Therefore, IC must equal 0 and 
EMM must equal 1. As depicted in Table 5, the collapsed 
categories (v  4) all yield IC  0 and EMM  1, suggest-
ing an interaction between E and comorbidity that does not 
exist. Furthermore, as v increases, the bias of IC decreases 
but the bias of EMM increases. In scenario 2, both the 
exposure and comorbidy affect the outcome. Collapsing the 
comorbidity categories can overestimate IC (when v = 3) or 
underestimate IC (when v  2). On the other hand, EMM is 
most overestimated in scenario 2 when v = 1.
Discussion
The common practice of collapsing the highest categories 
of comorbidity into a single category has the advantages of 
increasing the prevalence of subjects in the highest category 
of comorbidity, thereby improving the ease of comprehen-
sion and the statistical effi ciency of the analysis. These 
advantages, however, come at the price of misclassifi cation 
of subjects. The impact of this misclassifi cation depends on 
how the comorbidity variable is used in the analysis.
When comorbidity is an exposure or predictor of the out-
come in the analysis, then the misclassifi cation changes the 
pattern of the outcome response as a function of the “dose” 
of comorbidity. This result should be expected; miscategori-
zation of dose – and in particular combining categories with 
dissimilar outcome risks – yields misleading dose-response 
patterns.10 Better analytic solutions are to collapse only 
adjacent comorbidity categories with similar risks6 or to use 
more sophisticated dose-response modeling, such as spline 
regression.10 The similarity of risks in adjacent categories is 
best left to judgment, perhaps informed by statistical testing, 
because of the poor power to detect important differences by 
statistical testing alone.11
When comorbidity is a candidate confounder in the 
analysis, then the misclassifi cation biases the relative risk due 
to confounding toward the null (assuming independent and 
nondifferential classifi cation errors). The result is residual 
confounding of the association between the exposure of 
interest and the outcome. This result should also be expected; 
independent and nondifferential misclassifi cation of a con-
founder is known to yield residual confounding.12 Importantly, 
misclassifi cation resulting from crude categorization of even 
a covariate that has been well-measured on a continuous 
scale can result in substantial bias.13 As above, better analytic 
solutions are to collapse only adjacent comorbidity categories 
with similar risks,6 to use spline regression,10,14 or to include 
Table 5 Depiction of the true IC and EMM (v = 4) and biased IC 
and EMM (v  4) when comorbidity categories are collapsed
v Scenario 1 Scenario 2
IC EMM IC EMM
4 0 1 0.298 1
3 0.156 1.73 0.339 1.87
2 0.088 1.72 0.186 1.83
1 0.086 2.46 0.150 2.68
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the comorbidity index as a single linear term in regression 
modeling.14 Restricting the study sample to subjects with 
comorbidity scores below the threshold where category 
collapsing will improve comprehensibility and statistical 
effi ciency is also an alternative, although this restriction may 
reduce the generalizability of study results.15
When comorbidity is a candidate modifi er in the analysis, 
then the misclassifi cation can give rise to the appearance of 
interaction when no interaction exists, can mask true inter-
action, and can bias the estimate of interaction.3 Different 
combinations of these possibilities may appear depending on 
whether interaction is assessed as departure from additive 
or multiplicative effects, both of which have been proposed 
as important considerations in the examination of comor-
bidity.1,4 This result should also be expected; independent 
and nondifferential misclassifi cation of a modifi er is known 
to affect analyses of interaction unpredictably.12 For most 
analyses of interaction, the best analytic solution is to restrict 
the analysis and inference to a category of comorbidity with 
uniform risk for the outcome.
The appeal of collapsing categories of comorbidity to 
facilitate interpretation and statistical analysis is often offset 
by misleading results. At a minimum, analysts should assure 
the uniformity of outcome risk in collapsed categories before 
collapsing them. Often times, more appropriate analytic 
methods can achieve similar goals without sacrifi cing the 
validity of the study’s results.
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